{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015520","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.105425+00:00","generated_at":"2026-06-24T02:59:05.214402+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Design Therapeutics reports Q2 net loss $15M; holds $359.4M cash; initial FA data expected Q4 2022","bullets":["Net loss of $15.0M for Q2 2022; R&D expenses $11.3M; G&A expenses $4.3M.","Cash, equivalents and securities totaled $359.4M as of June 30, 2022, providing multi-year runway.","Initial Phase 1 single-ascending dose data for DT-216 in Friedreich ataxia expected Q4 2022.","Clinical development for myotonic dystrophy type-1 GeneTAC program anticipated in 2023.","Preclinical FECD program advancing; molecules showed nearly complete reduction in toxic RNA foci in vitro."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015520","json":"https://secwatch.observer/filing/0000950170-22-015520.json","markdown":"https://secwatch.observer/filing/0000950170-22-015520.md","text":"https://secwatch.observer/filing/0000950170-22-015520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017022015520/0000950170-22-015520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017022015520/dsgn-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:59:05.214402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}